scispace - formally typeset
M

Marta Palmieri

Researcher at University of Verona

Publications -  73
Citations -  9230

Marta Palmieri is an academic researcher from University of Verona. The author has contributed to research in topics: Pancreatic cancer & Gene. The author has an hindex of 35, co-authored 72 publications receiving 7850 citations.

Papers
More filters
Journal ArticleDOI

Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells.

TL;DR: The role of ROS and of ROS-related microRNAs in the establishment and maintenance of self-renewal and differentiation capacities of CSCs are described.
Journal ArticleDOI

Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB.

TL;DR: To characterize the mechanisms underlying apoptosis induced by viral infection, transcriptional activation of genes encoding members of the ‘BH3-only’ family of proteins was analysed during the course of virus infection and correlated with a covalent linkage with a previously unknown regulatory polypeptide.
Journal ArticleDOI

Regulation of Autophagy by Nuclear GAPDH and Its Aggregates in Cancer and Neurodegenerative Disorders.

TL;DR: The molecular mechanisms and the cellular effects of GAPDH aggregates, which are correlated with mitochondrial malfunctions and can be considered a potential therapeutic target for various diseases, including cancer and neurodegenerative disorders are summarized.
Journal ArticleDOI

Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon-gamma.

TL;DR: It is demonstrated that in HeLa cells, induction of IL‐6 by interferon‐γ (IFN‐γ) is transcriptionally controlled, as shown by run on assays and analysis of the IL‐ 6 mRNA stability.
Journal ArticleDOI

Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis

TL;DR: The results demonstrate for the first time a survival role for autophagy induced by p53-reactivating molecules, supporting the development of an anti-cancer therapy based on autophagic inhibition associated to p53 activation.